Related Experiment Videos
[Converting enzyme inhibitors and cardiac insufficiency: current findings and perspectives]
A Cohen-Solal1, T Laperche, S Makowski
1Service de cardiologie, hôpital Bichat, Paris.
Insights
Angiotensin-converting enzyme inhibitors offer sustained benefits for chronic heart failure patients, improving survival in severe cases. Ongoing research explores their potential as a primary treatment option.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Abstract:
Angiotensin-converting enzyme inhibitors are mixed vasodilators with a prolonged sustained effect in chronic heart failure. They also act on the reactivity of peripheral circulation, on ventricular remodelling after myocardial infarction, on myocardial hypertrophy in arterial hypertension and on ventricular hyperexcitability. They alleviate the symptoms of symptomatic heart failure, and they constitute the only treatment that has been able to improve the survival of patients with the most severe heart failure. Several studies are in progress to determine whether these drugs should be used as first-line therapy.